尿核基质蛋白22作为镜下血尿患者尿路上皮癌筛查的新标志物。

Urinary nuclear matrix protein 22 as a new marker for the screening of urothelial cancer in patients with microscopic hematuria.

作者信息

Miyanaga N, Akaza H, Tsukamoto T, Ishikawa S, Noguchi R, Ohtani M, Kawabe K, Kubota Y, Fujita K, Obata K, Hirao Y, Kotake T, Ohmori H, Kumazawa J, Koiso K

机构信息

University of Tsukuba, Japan.

出版信息

Int J Urol. 1999 Apr;6(4):173-7. doi: 10.1046/j.1442-2042.1999.06437.x.

DOI:10.1046/j.1442-2042.1999.06437.x

PMID:10226833

Abstract

PURPOSE

The aim of the present study was to determine the clinical usefulness of nuclear matrix protein 22 (NMP22) as a new urinary marker for the screening of urothelial cancer in patients with microscopic hematuria, especially in comparison with that of voided urine cytology.

METHODS

Patients with microscopic hematuria detected at a health examination, who were advised by a consulted urologist to have a cystoscopical examination, were asked to enter this study. Urine samples were collected before cystoscopy and divided into two portions for NMP22 test and voided urine cytology.

RESULTS

Of the 309 patients with microscopic hematuria, 22 cases (7.1%) of urothelial cancer and one case of prostate cancer were detected. For the other cases, 128 (41.4%) were of benign diseases and 158 (51.1%) were designated as having no evidence of disease (NED). The median NMP22 values for urothelial cancer, other diseases and NED were 35.5, 6.7 and 6.0 U/mL, respectively, with 95% confidence intervals of 19.9-228.2, 5.1-9.3 and 5.4-7.2, respectively. The sensitivity of the NMP22 test for urothelial cancer was 90.9% (20/22), whereas the sensitivity of voided urine cytology was only 54.5% (12/22).

CONCLUSIONS

The present study indicates that urinary NMP22 is a useful tool for the screening of urothelial cancer in patients with microscopic hematuria.

摘要

目的

本研究旨在确定核基质蛋白22（NMP22）作为一种新的尿液标志物在筛查镜下血尿患者尿路上皮癌中的临床应用价值，特别是与尿脱落细胞学检查进行比较。

方法

在健康体检中检测出镜下血尿的患者，经咨询泌尿外科医生建议进行膀胱镜检查，邀请这些患者参加本研究。在膀胱镜检查前收集尿液样本，分为两份分别用于NMP22检测和尿脱落细胞学检查。

结果

在309例镜下血尿患者中，检测出22例（7.1%）尿路上皮癌和1例前列腺癌。其他病例中，128例（41.4%）为良性疾病，158例（51.1%）被判定为无疾病证据（NED）。尿路上皮癌、其他疾病和NED患者的NMP22中位数分别为35.5、6.7和6.0 U/mL，95%置信区间分别为19.9 - 228.2、5.1 - 9.3和5.4 - 7.2。NMP22检测尿路上皮癌的敏感性为90.9%（20/22），而尿脱落细胞学检查的敏感性仅为54.5%（12/22）。